5-MeO-PiPT

Last updated

5-MeO-PiPT
5-MeO-PiPT.svg
Clinical data
Other names5-Methoxy-N-propyl-N-isopropyltryptamine
Drug class Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(propan-2-yl)propan-1-amine
CAS Number
PubChem CID
Chemical and physical data
Formula C17H26N2O
Molar mass 274.408 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC)CCc1c[NH]c2ccc(cc21)OC
  • InChI=1S/C17H26N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h6-7,11-13,18H,5,8-10H2,1-4H3
  • Key:KLRSMSBDLVDLKK-UHFFFAOYSA-N

5-MeO-PiPT, also known as 5-methoxy-N-propyl-N-isopropyltryptamine, is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a serotonin 5-HT1A and 5-HT2A receptor agonist, [1] with an EC50 of 13.8 nM and an efficacy of 89% (vs 5-HT), [2] and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada. [3]

Contents

Interactions

See also

References

  1. ↑ Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D (June 2024). "Structural pharmacology and therapeutic potential of 5-methoxytryptamines". Nature. 630 (8015): 237–246. Bibcode:2024Natur.630..237W. doi:10.1038/s41586-024-07403-2. PMC   11152992 . PMID   38720072.
  2. ↑ Patentscope. Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167. Retrieved 2025-05-12
  3. ↑ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia's Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.